Impact of Selective Adenosine A2AReceptor Agonists on Cardiac Imaging Feeling the Lightning, Waiting on the Thunder**Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology. by Miller, D. Douglas
EI
A
A
F
W
D
S
A
s
i
S
1
a
n
t
a
c
t
i
d
n
w
a
e
c
m
i
T
I
fi
a
r
i
m
v
A
M
U
r
a
o
I
i
Journal of the American College of Cardiology Vol. 46, No. 11, 2005
© 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00
Pi
s
a
d
l
b
b
q
(
o
i
r
s
[
s
e
t
d
w
a
I
h
a
d
t
b
r
a
d
o
t
g
b
T
U
F
r
d
F
t
t
h
a
t
t
t
r
p
a
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.07.061DITORIAL COMMENT
mpact of Selective
denosine A2A Receptor
gonists on Cardiac Imaging
eeling the Lightning,
aiting on the Thunder*
. Douglas Miller, MD, CM, FACC
t. Louis, Missouri
pproximately equal numbers of thunderstorms and cardiac
tress imaging studies occur daily around the world (approx-
mately 40,000). The U.S. National Center for Health
tatistics reported 1,318 deaths from lightning from 1980 to
995 (1). In the same era, multi-center registries of 89,973
denosine (2) and dipyridamole (3,4) testing reported only
ine cardiac deaths (0.0001%). As such, one is more likely
o be killed by a random lightning strike than to die during
vasodilator stress imaging study.
See page 2069
Despite this reassuring mortality tilt in favor of pharma-
ological stress, there continues to be test tolerability issues
hat reduce patient comfort during cardiac drug stress
maging—let’s call these troublesome side effects the thun-
er. In other reports (4,5), more than one-third of patients
ote flushing, dyspnea, and chest pain after adenosine,
hereas 10% to 20% of patients receiving either of the Food
nd Drug Administration (FDA) approved agents experi-
nce headache, dizziness, or transient electrocardiographic
hanges. The most feared non-lethal complications—
yocardial infarction (MI) and bronchospasm—occurred
n 0.15% of tests.
HE LITERATURE
n this issue of the Journal, Hendel et al. (6) report the
ndings of a Phase 2 study designed to establish the safest
nd most efficacious bolus dose of new selective A2A
eceptor agonist (regadenoson) in subjects with clinically-
ndicated adenosine single-photon emission computed to-
ography (SPECT) scans. The requirement for a predom-
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Department of Internal Medicine, Saint Louis University School of
edicine, St. Louis, Missouri. The department of internal medicine at Saint Louis
niversity has received or is receiving research support for studies of all three A2A
eceptor agonists from King Pharmaceuticals, Cardiovascular Therapeutics (CVT),
nd Bristol-Myers Squibb (BMS). Dr. Miller was the local site principal investigator
n the Phase III CVT study and is a sub-investigator for the Phase III BMS study.s
n the context of these multi-center studies, Dr. Miller has participated in required
nvestigator meetings. He is a member of the BMS Speakers Bureau.nantly reversible myocardial perfusion defect suggests a
tudy population with a high pre-test likelihood of coronary
rtery disease (CAD). The open-label, unblinded trial
esign compared patient tolerability of two randomly se-
ected intravenous (IV) boluses (400 or 500 g). On the
asis of the side effect profile of the higher dose, the
etter-tolerated 400-g bolus was selected for the subse-
uent Phase 3 trial, despite two serious adverse events
SAEs).
Although the statistical rigor of the study was limited,
wing to small sample size, adenosine-regadenoson SPECT
mage agreement was good (86%) and comparable to that
eported when sequential dipyridamole and adenosine SPECT
cans were compared in the same patients (87% [7] and 90%
8], respectively). The reproducibility of two serial adeno-
ine SPECT studies in the same patient has never been
stablished. As such, the equivalency of a regadenoson bolus
o an adenosine infusion for reversible SPECT perfusion
efect detection could not be determined.
The current study is comparable to a previous study (9) in
hich another A2A agonist (binodenoson) was administered
s either a 3-min 1.5-g/kg IV infusion or as a range of 30-s
V boluses. Of the subjects, 98% had known CAD (90%) or
igh pre-test CAD likelihood (8%). Overall, binodenoson-
denosine SPECT concordance was good-to-excellent for
efect extent and severity (79% to 87%). Kappa statistics in
his larger population ranged from 0.69 to 0.85, supporting
inodenoson’s SPECT comparability to adenosine. Patient-
eported adverse effects (AEs) were similar with both
gents, but AE severity was less with binodenoson. High-
egree atrioventricular (AV) block only occurred with aden-
sine. Separate pharmacokinetic studies in healthy volun-
eers showed good tolerability, with dose-dependent and
enerally mild AEs occurring over a range of binodenoson
oluses (10).
HE DRUG APPROVAL AGENDA
nder the Federal Food, Drug and Cosmetic Act, the
DA’s Center for Drug Evaluation and Research has a
esponsibility to assure the safe and effective use of approved
rugs by prescribers and patients (11). What does the
DA’s Cardio-Renal Panel want from thedenoson clinical
rialists and sponsors before approving a Phase 3 clinical
rial? Although the panel reviews the pre-clinical data and
uman subject AEs in Phases 1 and 2, it is more appropri-
tely concerned about the SAEs that threaten patient safety
han nuisance complaints that limit tolerability. Investiga-
ional new drugs (INDs) must prove to be as safe as or safer
han drugs already in clinical use. Binodenoson (9) and
egadenoson (6) Phase 2 trials were free of feared cardio-
ulmonary SAEs that are rarely observed after adenosine
nd dipyridamole (i.e., stroke, MI, death, and broncho-
pasm).
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December 6, 2005:2076–8 Editorial CommentData gathered during pre-clinical and clinical trials be-
ome part of the New Drug Application (NDA), which
ust be FDA-approved before U.S. commercialization.
ifferent regulations and requirements exist under the aegis
f the European Union’s Agency for Evaluation of Medic-
nal Products (12).
Sponsors of denoson INDs primarily seek a product-
abeling claim on the package insert of comparable safety
nd efficacy to adenosine. Better safety might be achievable
n the basis of highly selective coronary vascular A2A
eceptor agonism, without A1-mediated AV conduction
ffects and A2B-mediated bronchoconstriction. Approval of
better tolerability claim would require that the denoson
ompounds reduce the frequency and/or severity of less
erious AEs. Reported rates of the three commonest vaso-
ilator AEs do not differ among adenosine, binodenoson,
nd regadenoson; so, available data do not yet support a
better tolerability” labeling claim for the A2A selective
gonists (Fig. 1).
No safety or tolerability claim would be meaningful
nless the FDA was assured that the new A2A agonists are
t least as efficacious as adenosine for the detection of
igure 1. Published rates of the most common vasodilator side effects of
denosine and dipyridamole (5), binodenoson (9), and regadenoson (6),
emonstrates similar patient tolerability for A2Aselective agonists to aden-
sine. Black bars  flushing; white bars dyspnea; ruled bars  chest
ain.
igure 2. Intracoronary Doppler flow-wire average peak velocity (APV) me
our minutes later by an IV bolus of MRE0470 (binodenoson). A two-fold incr
C adenosine bolus. Coronary hyperemia after IV binodenoson bolus administreversible myocardial hypoperfusion (“ischemia”). The FDA
equires multiple scoring approaches for the core lab com-
arison of SPECT studies. The current study (6) used
linded experts to score regadenoson and adenosine
PECT scans twice, in both random order and in side-by-
ide fashion. Despite reader expertise, regadenoson SPECT
as 11% to 18% discordant with adenosine overall and 11%
o 24% discordant in the rating of myocardial “ischemia.”
ormal-versus-abnormal scan classification and degrees-of-
efect abnormality classification also produced different
oncordances. No angiographic “gold standard” comparison
as required by the FDA in Phase 2 to confirm denoson
can accuracy for detecting coronary stenoses (6,9); the
DA is seeking this information in one ongoing Phase 3
rial.
Flow- and pressure-wire devices are widely used in the
linical setting to assess whether intermediate coronary
esions are flow-limiting (13). “In-cath. lab.” physiological
esting of drug-induced coronary hyperemia emerged as a
aluable means of establishing the dose-dependent potency
f these new denoson agents (Fig. 2), and for determining
he timeline of drug effect (14).
HE MARKETPLACE
y design, Phase 2 studies of these new selective A2A
gonists excluded patients with asthma or known broncho-
pasm, high-degree AV block, recent MI, and depressed left
entricular ejection fraction. By design, and to maximize
ischemic” defects, the majority of Phase 2 subjects had
ither known CAD or a high pre-test CAD likelihood.
ome Phase 3 studies are limiting enrollment of subjects
ith a 10% pre-test CAD likelihood to increase the
ikelihood of coronary angiographic correlations. By design,
he current study (6) excluded subjects weighing 250 lbs.
oth studies enrolled mostly men (64% [9] and 75% [6]),
nd both included patients with an average age of 65 to 67
ears. These pre-determined exclusions appropriately re-
uced the risk to research subjects. They also increased the
ments after three successive intracoronary (IC) adenosine boluses, followedasure
ease in APV is observed after an IV binodenoson bolus, comparable to an
ation lasts three to four minutes. Reprinted with permission (14).
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Editorial Comment December 6, 2005:2076–8otential for differences in the anticipated denoson expe-
ience in the clinical setting. Safety, tolerability, SPECT
efect detection, and angiographic correlates could vary in
eal-world referral populations.
Sponsors marketing these agents might exploit the pa-
ient throughput and technical advantages of bolus dosing.
uch diagnostic utilities could eventually be a basis for
ompetitive product positioning. Although field use must be
onsistent with the package insert, wider practical experi-
nce and technical advances in drug delivery systems have
reviously led clinicians to modify the FDA-approved drug
osing and imaging protocols. “Off-label” applications have
roven useful by shortening adenosine infusion times, aug-
enting demand stress, or accentuating myocardial defect
eversibility with nitroglycerine pre-treatment. Similar modi-
cations intended to improve testing efficiency and/or
iagnostic yield of selective A2A agonists should ideally be
upported by evidence-based modifications to the package
nsert.
HE FORECAST
t is a truism, long held by Midwestern farmers, that
lightning doesn’t strike twice in the same spot;” however,
ith the recent advent of highly selective coronary A2A
eceptor agonists with the denoson suffix, three of which
re in the process of passing the obstacles on the way to
DA approval, industry’s new drug development efforts in
esponse to patient safety and test tolerability concerns will
ause lightning to strike. . .not once, not twice, but thrice!!!
nother denoson (i.e., Bristol-Myers Squibb apadenoson)
as also entered Phase 3, after demonstrating dose-
ependent potency, safety, and efficacy in Phase 2.
Clinicians and the FDA want to know if the denosons
ill outperform the approved “old standards” (adenosine
nd dipyridamole). Pilot studies (6,9) suggest that the safety
nd test tolerability attributes of these A2A receptor agonists
re a class effect. The rigor with which these novel phar-
acological stress agents are each being studied is unparal-
eled. This bodes well for patients and doctors who, after a
orrential burst of clinical investigation, should have a
hoice of safer and better-tolerated new drugs to assist in
AD diagnosis and risk stratification.
The summer storm season is upon us. Children anxiously
waking to the crash of thunder will be reassured by
atchful parents that additional seconds counted between a
ightning flash and the ensuing rumble reflect the storm’s
assing and safety. It remains to be seen whether the FDA’s
pproval of regadenoson and binodenoson will translate into
rst-to-market advantages for sponsors or whether the
orona of St. Elmo’s fire, usually visible after the worst of anlectrical storm, will reveal yet another denoson’s superior-
ty and signal clearer skies ahead for stress imagers.
eprint requests and correspondence: Dr. D. Douglas Miller,
rofessor and Chair, Department of Internal Medicine, Saint
ouis University School of Medicine, 1402 Grand Boulevard, St.
ouis, Missouri 63104. E-mail: millerdd@slu.edu.
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